Idexx Laboratories Inc
Research Idexx Laboratories Inc (IDXX) on Bullrun: valuation model: 11.4% overvalued, market cap USD 41.33B, P/E 36.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIDXX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal11.4% overvalued
- Market capUSD 41.33B
- P/E36.8
- Financial periodQ2 2026
- RevenueUSD 1.22B
- Net incomeUSD 338.41M
- Free cash flowUSD 320.62M
- Gross margin64.0%
Valuation Snapshot
Bullrun's latest valuation model marks Idexx Laboratories Inc as 11.4% overvalued; latest market cap is USD 41.33B; P/E is 36.8.
Peer valuation comparison
Latest P/E is 36.82x versus a Healthcare sector median of 24.6x (49.7% above).
Latest P/E is 36.82x versus a United States median of 23.85x (54.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.30B | USD 1.06B | USD 1.06B | 61.8% | 13.08 | USD 180.07M | USD 449.84M | USD 1.61B |
| FY2024 | USD 3.90B | USD 887.87M | USD 808.08M | 61.0% | 10.67 | USD 288.27M | USD 617.57M | USD 1.60B |
| FY2023 | USD 3.66B | USD 845.04M | USD 772.88M | 59.8% | 10.06 | USD 453.93M | USD 697.88M | USD 1.48B |
| FY2022 | USD 3.37B | USD 679.09M | USD 394.15M | 59.5% | 8.03 | USD 112.55M | USD 769.37M | USD 608.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 41.33B | 36.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 53.93B | 51.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 33.74B | 38.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 46.10B | 56.6 | n/a | n/a |
| 2022 | 2022-12-30 | USD 33.79B | 51.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 55.68B | 76.6 | n/a | n/a |
About Idexx Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers;
ETFs that hold Idexx Laboratories Inc
Idexx Laboratories Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| iShares US Medical Devices UCITS ETF USD (Acc) | 4.27% | 0.25% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Idexx Laboratories Inc overvalued or undervalued?
Bullrun's valuation model currently marks Idexx Laboratories Inc as 11.4% overvalued.
What is Idexx Laboratories Inc's market cap?
Idexx Laboratories Inc's market capitalization is USD 41.33B.
What is Idexx Laboratories Inc's P/E ratio?
Idexx Laboratories Inc's price-to-earnings (P/E) ratio is 36.8.
What does Idexx Laboratories Inc do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.